COVID-19: What we know
Abstract
A concise overview synthesizes early knowledge on COVID‑19 in pediatrics, covering transmission, clinical spectrum, diagnostics, and prevention, and pointing to priorities for longitudinal study.
Author Contributions
Academic Editor: Ibrahim Hassan Ibrahim, Prof. of Animal Physiology, Department of radioactive isotopes
Checked for plagiarism: Yes
Review by: Single-blind
Copyright © 2020 Stefan Bittmann

Competing interests
The authors have declared that no competing interests exist.
Citation:
Letter
SARS-CoV-2 coronavirus infection outbreak has been reported in December 2019 in Wuhan, China (1-4). COVID 19 corona disease seems to be different from children and adults. The question is why? To date, there have been only few fatal in childhood, in complete difference to adults. Till 26 of March 2020, WHO registered 2401 deaths worldwide. A series and devastating new virus spreading at an extremely rapid pace all over the world. More than 100.000 infections were found in the US until the date of this publication.
What we know, COVID 19 could be a result of a similar coronavirus in bats, spreading exponential, one human transmitter infects 3 people, 3 infected patients infect themselves to nine, and so on. Chinese researchers floot their young research articles about COVID 19 to western journals. What we know, COVID-19 will kill many people, and, children. COVID 19 infects the lungs leading to severe crown pneumonia and later ARDS. What we know, that older patients with disabilities and underlying diseases like hypertension and diabetes are at greater risk for developing a fatal outcome in COVID-19. The search for drugs and research efforts in developing a vaccination is at high speed. COVID-19 binds with spike protein to the angiotensin-II receptor. Vaccination research focuses on inactivating spike protein and the binding domain. The receptor binding domain is well known. Research must concentrate intensively on blocking and inactivate the spike protein receptor domain of COVID-19. Drug theories think about blocking the angiotensin II receptor by Losartan or another angiotensin II blocker, that COVID 19 can’t bind to ACE2. What we know is that in some severe cases of Losartan treatment, the patient course was more fatal. At the University of Minnesota, a randomized trial was introduced on 16/03/2020 in 200 patients to prove the advantage of Losartan in the treatment of COVID-19 patients. Attempts to give children lopinavir/retinavir sirup was introduced in China few weeks after outbreak in Wuhan, in children. What we know, all given drugs, hydrocloroquin, Losartan, lopinavir/retinavir, antibody-rich plasma from survivors show, to date, no overwhelming therapeutical effect in COVID-19 patients. What we know is, that in children, a higher level of procalcitonin, a higher level of dimere and surprisingly, a higher level of creatine kinase MB is oenzyme was found, suggesting a myocardial potential. Research efforts in general are in childhood shoes are due to the extremely rapid spreading of this novel virus a challenge for the human being.
What we know, COVID-19 will change our lives, our world.
Cited by (26)
This article has been cited by 26 scholarly works according to:
Citing Articles:
N. Garnier, F. Sane, Layal Massara, F. Soncin, P. Gosset et al. - Viruses (2023) Semantic Scholar
O. Gaidai, P. Yan, Y. Xing, Jingxiang Xu, Yu Wu - F1000Research (2022) Semantic Scholar
Kamil Reza Khondakar, A. Kaushik - Biosensors (2022) Semantic Scholar
PLoS Computational Biology (2021) OpenAlex
Pavel D. Pankov, M. K. Salpagarov, N. Yakovleva, Alexey V. Andronov, G. A. Baranov et al. - (2021) Semantic Scholar
City Healthcare (2021) OpenAlex
David Segal, Yonatan Ilibman Arzi, M. Bez, Matan Cohen, Jacob Rotschield et al. - Military Medicine (2021) Semantic Scholar
Ya-jing Hou, Shuai Ge, Xiaowei Li, Cheng Wang, Huaizhen He et al. - Chemico-Biological Interactions (2021) Semantic Scholar
S. Bittmann - (2020) Semantic Scholar
M. Humayun - (2020) Semantic Scholar
Maheswari Nagendran, J. John, Kavithakani Annamalai, Muthu Iswarya Gandhi Sethuraman, Nirkayani Balamurugan et al. - Journal of Drug Delivery Science and Technology (2020) Semantic Scholar
Mohsen Rokni, K. Ahmadikia, S. Asghari, Shahabodin Mashaei, F. Hassanali - BMC Infectious Diseases (2020) Semantic Scholar
Romanian Journal of Internal Medicine (2020) OpenAlex
Albaraa A Milibari - (2020) Semantic Scholar
Uzair Ahmed, U. Ashfaq, S. Khaliq, M. Qasim, S. Jahan et al. - Journal of Microbiology and Infectious Diseases (2020) Semantic Scholar
S. Bittmann - (2020) Semantic Scholar
S. Daoud, Shada J. Alabed, Lina A. Dahabiyeh - Acta Pharmaceutica (2020) Semantic Scholar
M. Soto, V. Guarner-Lans, E. Soria-Castro, L. Manzano Pech, I. Pérez-Torres - Medicina (2020) Semantic Scholar
David Segal, Jacob Rotschield, Ran Ankory, S. Kutikov, Bian Moaddi et al. - Military Medicine (2020) Semantic Scholar
B. E. Falcón-Guerrero, Guido Sebastián Falcón-Pasapera - (2020) Semantic Scholar
Mohammad Ridwane Mungroo, N. Khan, R. Siddiqui - Pathogens (2020) Semantic Scholar
E. Stachowska, M. Folwarski, D. Jamioł-Milc, D. Maciejewska, K. Skonieczna-Żydecka - Medicina (2020) Semantic Scholar
M. S. Mian, Laiba Razaq, Safeera Khan, N. Hussain, M. Razaq - Cureus (2020) Semantic Scholar
Mohammed Ahmad, A. Dwivedy, R. Mariadasse, S. Tiwari, Deepsikha Kar et al. - ACS Omega (2020) Semantic Scholar
Haiyue Liu, Aqsa Manzoor, Cangyu Wang, Lei Zhang, Zaira Manzoor - International Journal of Environmental Research and Public Health (2020) Semantic Scholar
F. Vella, P. Senia, Manuela Ceccarelli, Ermanno Vitale, H. Maltezou et al. - European Review for Medical and Pharmacological Sciences (2020) Semantic Scholar